(Q33394804)
Statements
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study (English)
Miguel Nogué
Pilar Vicente
Antonio Arriví
José María Roca
Ferran Losa
José Ponce
María José Safont
Inmaculada Guasch
Isabel Moreno
Ana Ruiz
AVACROSS Study Group
1 reference
1 reference